

# Anne Sofie Siebuhr

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/7565263/anne-sofie-siebuhr-publications-by-citations.pdf>

**Version:** 2024-04-29

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

34  
papers

848  
citations

15  
h-index

29  
g-index

35  
ext. papers

1,036  
ext. citations

3.9  
avg, IF

3.84  
L-index

#	Paper	IF	Citations
34	Disease-modifying treatments for osteoarthritis (DMOADs) of the knee and hip: lessons learned from failures and opportunities for the future. <i>Osteoarthritis and Cartilage</i> , <b>2016</b> , 24, 2013-2021	6.2	180
33	Identification and characterisation of osteoarthritis patients with inflammation derived tissue turnover. <i>Osteoarthritis and Cartilage</i> , <b>2014</b> , 22, 44-50	6.2	73
32	The active form of MMP-3 is a marker of synovial inflammation and cartilage turnover in inflammatory joint diseases. <i>BMC Musculoskeletal Disorders</i> , <b>2014</b> , 15, 93	2.8	67
31	Serological identification of fast progressors of structural damage with rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , <b>2013</b> , 15, R86	5.7	63
30	Association between biomarkers of tissue inflammation and progression of osteoarthritis: evidence from the Rotterdam study cohort. <i>Arthritis Research and Therapy</i> , <b>2016</b> , 18, 81	5.7	61
29	Type X collagen levels are elevated in serum from human osteoarthritis patients and associated with biomarkers of cartilage degradation and inflammation. <i>BMC Musculoskeletal Disorders</i> , <b>2014</b> , 15, 309	2.8	43
28	Sprifermin (rhFGF18) modulates extracellular matrix turnover in cartilage explants ex vivo. <i>Journal of Translational Medicine</i> , <b>2017</b> , 15, 250	8.5	38
27	Inflammation (or synovitis)-driven osteoarthritis: an opportunity for personalizing prognosis and treatment?. <i>Scandinavian Journal of Rheumatology</i> , <b>2016</b> , 45, 87-98	1.9	35
26	Cartilage turnover reflected by metabolic processing of type II collagen: a novel marker of anabolic function in chondrocytes. <i>International Journal of Molecular Sciences</i> , <b>2014</b> , 15, 18789-803	6.3	32
25	Matrix metalloproteinase-dependent turnover of cartilage, synovial membrane, and connective tissue is elevated in rats with collagen induced arthritis. <i>Journal of Translational Medicine</i> , <b>2012</b> , 10, 195	8.5	30
24	Synovitis biomarkers: ex vivo characterization of three biomarkers for identification of inflammatory osteoarthritis. <i>Biomarkers</i> , <b>2015</b> , 20, 547-56	2.6	27
23	Early changes in blood-based joint tissue destruction biomarkers are predictive of response to tocilizumab in the LITHE study. <i>Arthritis Research and Therapy</i> , <b>2016</b> , 18, 13	5.7	22
22	Serological biomarkers of joint tissue turnover predict tocilizumab response at baseline. <i>Journal of Clinical Rheumatology</i> , <b>2014</b> , 20, 332-5	1.1	16
21	Dermal fibroblasts have different extracellular matrix profiles induced by TGF- $\beta$ PDGF and IL-6 in a model for skin fibrosis. <i>Scientific Reports</i> , <b>2020</b> , 10, 17300	4.9	16
20	Chondrocyte activity is increased in psoriatic arthritis and axial spondyloarthritis. <i>Arthritis Research and Therapy</i> , <b>2016</b> , 18, 141	5.7	15
19	Serum biomarkers of collagen turnover as potential diagnostic tools in diffuse systemic sclerosis: A cross-sectional study. <i>PLoS ONE</i> , <b>2018</b> , 13, e0207324	3.7	15
18	Sprifermin (rhFGF18) versus vehicle induces a biphasic process of extracellular matrix remodeling in human knee OA articular cartilage ex vivo. <i>Scientific Reports</i> , <b>2020</b> , 10, 6011	4.9	13

17	The Anti-ADAMTS-5 Nanobody M6495 Protects Cartilage Degradation Ex Vivo. <i>International Journal of Molecular Sciences</i> , <b>2020</b> , 21,	6.3	13
16	Suppression of active, but not total MMP-3, is associated with treatment response in a phase III clinical study of rheumatoid arthritis. <i>Clinical and Experimental Rheumatology</i> , <b>2018</b> , 36, 94-101	2.2	11
15	Investigating the Robustness and Diagnostic Potential of Extracellular Matrix Remodelling Biomarkers in Alkaptonuria. <i>JIMD Reports</i> , <b>2015</b> , 24, 29-37	1.9	10
14	Association between biochemical cartilage markers and clinical symptoms in patients with hip osteoarthritis: cohort study with 2-year follow-up. <i>Osteoarthritis and Cartilage</i> , <b>2015</b> , 23, 57-62	6.2	9
13	CRP and a biomarker of type I collagen degradation, C1M, can differentiate anti-inflammatory treatment response in ankylosing spondylitis. <i>Biomarkers in Medicine</i> , <b>2016</b> , 10, 197-208	2.3	8
12	Cartilage collagen type II seromarker patterns in axial spondyloarthritis and psoriatic arthritis: associations with disease activity, smoking and HLA-B27. <i>Rheumatology International</i> , <b>2016</b> , 36, 541-9	3.6	8
11	Metabolites of type I, II, III, and IV collagen may serve as markers of disease activity in axial spondyloarthritis. <i>Scientific Reports</i> , <b>2019</b> , 9, 11218	4.9	7
10	Citrullinated vimentin and biglycan protein fingerprints as candidate serological biomarkers for disease activity in systemic sclerosis: a pilot study. <i>Biomarkers</i> , <b>2019</b> , 24, 249-254	2.6	7
9	Type I and III collagen turnover is increased in axial spondyloarthritis and psoriatic arthritis. Associations with disease activity and diagnostic capacity. <i>Clinical and Experimental Rheumatology</i> , <b>2017</b> , 35, 653-659	2.2	6
8	Metabolites of C-reactive protein and vimentin are associated with disease activity of axial spondyloarthritis. <i>Clinical and Experimental Rheumatology</i> , <b>2019</b> , 37, 358-366	2.2	6
7	Association of metabolites reflecting type III and VI collagen formation with modified Rodnan skin score in systemic sclerosis - a cross-sectional study. <i>Biomarkers</i> , <b>2019</b> , 24, 373-378	2.6	4
6	Intercritical circulating levels of neo-epitopes reflecting matrixmetalloprotease-driven degradation as markers of gout and frequent gout attacks. <i>Rheumatology</i> , <b>2016</b> , 55, 1642-6	3.9	3
5	Circulating collagen neo-epitopes and their role in the prediction of fibrosis in patients with systemic sclerosis: a multicentre cohort study. <i>Lancet Rheumatology, The</i> , <b>2021</b> , 3, e175-e184	14.2	3
4	Is radiographic progression in radiographic axial spondyloarthritis related to matrix metalloproteinase degradation of extracellular matrix?. <i>RMD Open</i> , <b>2018</b> , 4, e000648	5.9	3
3	Effect of n-3 PUFA on extracellular matrix protein turnover in patients with psoriatic arthritis: a randomized, double-blind, placebo-controlled trial. <i>Rheumatology International</i> , <b>2021</b> , 41, 1065-1077	3.6	2
2	Objective and noninvasive biochemical markers in rheumatoid arthritis: where are we and where are we going?. <i>Expert Review of Proteomics</i> , <b>2021</b> , 18, 159-175	4.2	1
1	Development of a highly sensitive chemiluminescence immunoassay for quantification of aggrecanase-generated ARGS aggrecan fragments in serum. <i>Osteoarthritis and Cartilage Open</i> , <b>2021</b> , 3, 100162	1.5	1